Alzinova AB (publ) (ALZ.ST) Stock Analysis
Verdict: AVOID
Alzinova faces critical insolvency risk with $0.32M cash vs $39.6M FCF burn, rendering severe shareholder dilution or default inevitable.
Investment score: 20/100
Analysis as of
Is Alzinova AB (publ) stock worth reviewing? The TradeMates thesis
The TradeMates model recommends AVOID for Alzinova AB. Pre-revenue operations, a near-exhausted cash balance ($0.32M), expanding net losses (-$26.27M in 2025), and extreme historical share dilution make the stock highly vulnerable to emergency financing dilutive events or insolvency.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Alzinova AB (publ) opportunities and risks
What speaks for ALZ.ST
- ALZ-101 clinical trial progression could yield positive Phase 1b/2 clinical data by mid-2027.
What speaks against ALZ.ST
- Imminent liquidity exhaustion and insolvency risk within months.
Frequently asked questions about Alzinova AB (publ) (ALZ.ST)
Is ALZ.ST stock a good investment?
The TradeMates model rates Alzinova AB (publ) as AVOID with an investment score of 20/100. The TradeMates model recommends AVOID for Alzinova AB. Pre-revenue operations, a near-exhausted cash balance ($0.32M), expanding net losses (-$26.27M in 2025), and extreme historical share dilution make the stock highly vulnerable to emergency financing dilutive events or insolvency. This is algorithmic model output, not personal investment advice.
Is ALZ.ST stock a buy?
The TradeMates model verdict for ALZ.ST is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.